The difference of the retinal structural and microvascular characteristics in patients with MOGAD-ON and AQP4-ON.

Publisher: BioMed Central Country of Publication: England NLM ID: 100968555 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2377 (Electronic) Linking ISSN: 14712377 NLM ISO Abbreviation: BMC Neurol Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

Neuromyelitis Optica* ; Optic Neuritis* ; Retinal Diseases*; Aquaporin 4 ; Autoantibodies ; Humans ; Myelin-Oligodendrocyte Glycoprotein ; Prospective Studies ; Retina ; Tomography, Optical Coherence

Background: Antibodies against myelin-oligodendrocyte-glycoprotein (MOG-Abs) associated disease (MOGAD) has been recognized as a disease entity. Optic neuritis (ON) is the most common symptom in MOGAD. To demonstrate the differences in retinal microvascular characteristics between patients with MOGAD-ON and aquaporin-4 antibody (AQP4-Ab) positive ON.
Methods: In a prospective study, optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) were used to measure retinal and microvascular parameters.
Results: Twenty-six MOGAD-ON eyes, 40 AQP4-ON eyes, and 60 control eyes were included in the study. The thickness of RNFL and GCC in MOGAD-ON eyes was significantly lower than that of HC (p < 0.001, respectively), but comparable to AQP4-ON eyes. The vessel density in retina capillary plexus (RCP) was reduced significantly in MOGAD-ON than that in AQP4-ON (p < 0.05, respectively). The visual accuracy was positively correlated with vessel density of superficial RCP in MOG-ON (p = 0.001) and positively correlated with the thickness of the inner retina layer in AQP4-ON (p < 0.001).
Conclusion: The retinal neuro-axonal damages between MOGAD-ON and AQP4-ON were comparable. Unlike AQP4-ON eyes, microvascular densities were significantly reduced in MOGAD-ON and were positively correlated with the deterioration of visual acuity in MOGAD-ON.
Trial Registration: Clinical and Imaging Patterns of Neuroinflammation Diseases in China (CLUE, NCT: 04106830).
(© 2022. The Author(s).)

Neurol Neuroimmunol Neuroinflamm. 2019 Feb 01;6(2):e538. (PMID: 30800721)
PLoS One. 2012;7(4):e34823. (PMID: 22536333)
J Clin Med. 2020 Jun 02;9(6):. (PMID: 32498362)
Brain Pathol. 2014 Jan;24(1):83-97. (PMID: 24345222)
Sci Rep. 2019 Jul 17;9(1):10371. (PMID: 31316082)
Front Neurol. 2020 Sep 02;11:932. (PMID: 33013632)
J Neuroinflammation. 2016 Nov 1;13(1):282. (PMID: 27802824)
J Cataract Refract Surg. 2004 Feb;30(2):287-90. (PMID: 15030802)
Clin Dermatol. 2015 Mar-Apr;33(2):140-6. (PMID: 25704934)
Ann Neurol. 2016 Apr;79(4):605-24. (PMID: 26836302)
Neurol Neuroimmunol Neuroinflamm. 2014 Oct 29;1(4):e40. (PMID: 25364774)
Am J Ophthalmol. 2018 Aug;192:47-55. (PMID: 29750948)
Br J Ophthalmol. 2020 Jun;104(6):842-845. (PMID: 31582363)
J Neurol Neurosurg Psychiatry. 2016 Apr;87(4):446-8. (PMID: 25749692)
Clin Exp Ophthalmol. 2015 Sep-Oct;43(7):673-82. (PMID: 25824961)
Ther Adv Neurol Disord. 2018 Mar 29;11:1756286418762083. (PMID: 29623106)
J Neurol. 2016 Jul;263(7):1343-8. (PMID: 27142716)
Eur J Neurol. 2019 Jan;26(1):168-174. (PMID: 30133068)
J Autoimmun. 1989 Apr;2(2):115-32. (PMID: 2765095)
Mult Scler. 2015 Feb;21(2):163-70. (PMID: 24948688)
J Neuroophthalmol. 2021 Dec 1;41(4):e424-e432. (PMID: 33136671)
Lancet Neurol. 2010 Sep;9(9):921-32. (PMID: 20723847)
J Neurosci Res. 2010 Oct;88(13):2877-88. (PMID: 20544823)
Neurology. 2015 Jul 14;85(2):177-89. (PMID: 26092914)
Mult Scler. 2016 Oct;22(12):1541-1549. (PMID: 26869529)
Br J Ophthalmol. 2019 Jun;103(6):789-796. (PMID: 30021816)
JAMA Neurol. 2014 Mar;71(3):276-83. (PMID: 24425068)
J Clin Diagn Res. 2016 Jul;10(7):NC05-9. (PMID: 27630874)
Nat Rev Neurol. 2019 Feb;15(2):89-102. (PMID: 30559466)
Mult Scler Relat Disord. 2019 May;30:48-50. (PMID: 30738279)
J Neurol. 2018 Jan;265(1):33-40. (PMID: 29101456)
J Neuroimmunol. 2017 Apr 15;305:19-28. (PMID: 28284341)
Mult Scler. 2015 May;21(6):678-88. (PMID: 25662342)
J Neuroimmunol. 2017 Dec 15;313:10-15. (PMID: 29153600)
Brain. 2020 May 1;143(5):1431-1446. (PMID: 32412053)
Mult Scler. 2020 Oct;26(11):1360-1371. (PMID: 31364464)
Neurology. 2016 Jun 14;86(24):2303-9. (PMID: 27225223)
J Neurochem. 2015 Nov;135(4):742-54. (PMID: 25930947)

Keywords: MOGAD; NMOSD; OCTA; Optic neuritis

0 (Aquaporin 4)
0 (Autoantibodies)
0 (Myelin-Oligodendrocyte Glycoprotein)
0 (anti-aquaporin 4 autoantibody)

Date Created: 20220827 Date Completed: 20220830 Latest Revision: 20220830

20231215

PMC9419345

10.1186/s12883-022-02848-2

36030231